General Information of Drug (ID: DML5V22)

Drug Name
PL8177 Drug Info
Indication
Disease Entry ICD 11 Status REF
Ulcerative colitis DD71 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DML5V22

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bremelanotide DM20LIM Hypoactive sexual desire dysfunction HA00 Approved [3]
Afamelanotide DMVWHTG Erythropoietic porphyrias 5C58.12 Approved [4]
Dersimelagon DMMO0SU Erythropoietic protoporphyria 5C58.12 Phase 3 [5]
AP-1030 DMBGA35 Metabolic disorder 5C50-5D2Z Phase 1/2 [6]
MT-II DMKT1DA Female sexual arousal dysfunction HA01.1 Investigative [7]
C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2 DMX7IVO Discovery agent N.A. Investigative [8]
Ac-YRMEHdFRWG-NH2 DMN2UKC Discovery agent N.A. Investigative [9]
C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2 DMM19SJ Discovery agent N.A. Investigative [8]
C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2 DMSIGJW Discovery agent N.A. Investigative [8]
C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2 DMUESCH Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanocortin receptor 1 (MC1R) TT0MV2T MSHR_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT05466890) Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, PK and Biomarkers With Oral Colon Delivery PL8177 in Adult Subjects With Active Ulcerative Colitis. U.S.National Institutes of Health.
2 Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration. Drugs R D. 2021 Dec;21(4):431-443.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5 Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis. Arthritis Res Ther. 2022 Sep 1;24(1):210.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Design of potent linear alpha-melanotropin 4-10 analogues modified in positions 5 and 10. J Med Chem. 1989 Jan;32(1):174-9.
8 Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
9 Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.